{
  "meta": {
    "timestamp": "2025-01-06T12:40:38.544004",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Eisai Co. Ltd.",
      "symbol": "ESALF",
      "analysis": {
        "historical": {
          "risk_score": 60,
          "key_risks": [
            "Regulatory challenges in key markets like the U.S. and Europe",
            "High costs and uncertainties associated with drug development",
            "Competition and pricing pressures in oncology and neurology",
            "Reliance on key products like Lenvima and Aricept for revenue"
          ],
          "controversies": [
            "Voluntary withdrawal of Belviq due to potential cancer risks",
            "Failure to secure marketing approval for lecanemab in the European Union"
          ],
          "environmental_issues": [
            "Commitment to carbon neutrality by 2040"
          ],
          "social_issues": [
            "Diversity, Equity, and Inclusion (DE&I) initiatives",
            "Patient-centric approach through the 'hhc' concept"
          ],
          "governance_issues": [
            "Navigating complex global regulatory environments",
            "Potential for legal and regulatory compliance issues"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Eisai Co., Ltd.\uff5cA human health care company",
              "snippet": "Welcome to the Eisai Official Corporate Website Eisai Co., Ltd. Page. Menu. Eisai's hhc Concept ... Open Innovation; Corporate Venture Capital; Close Back. Research and Development (R&D) Research and Development (R&D) Eisai's Drug Discovery, Research and Development Sites Worldwide ... Eisai Staff in Charge Talks About Overcoming Challenges on ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205459+00:00",
              "published_date": null,
              "source_hash": "c816cf54051df8a8c6956447178b8e95"
            },
            {
              "url": "",
              "title": "LEQEMBI Alzheimer's treatment approved in Mexico | Eisai US",
              "snippet": "Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. 3.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205597+00:00",
              "published_date": null,
              "source_hash": "e0f89c181f31e5818d4f76eb01639428"
            },
            {
              "url": "",
              "title": "Eisai (company) - Wikipedia",
              "snippet": "Nihon Eisai Co. Ltd. was established in 1941. [4] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd. [5] The American subsidiary of the company, Eisai Inc., was established in 1995. [6]On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (), a drug discovered in the company's labs and co ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292284+00:00",
              "published_date": null,
              "source_hash": "dea3dfe6ae8da10c89b00710e980c186"
            },
            {
              "url": "",
              "title": "Eisai Co, Ltd | Access to Medicine",
              "snippet": "The full report card of Eisai Co, Ltd in PDF format. Download the report card . Performance in the 2024 Index. 14th place. ... Eisai received FDA approval for lecanemab-irmb (LEQEMBI\u00ae), a treatment for Alzheimer's disease. ... Eisai remains engaged in an existing IP-sharing agreement with a public research institution to accelerate drug ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205660+00:00",
              "published_date": null,
              "source_hash": "e2034385863f03ff8870533fb77566b8"
            },
            {
              "url": "",
              "title": "Information | Eisai Co., Ltd.",
              "snippet": "Eisai Inc.'s U.S. Headquarters Earns Three Key Building Certifications Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness. March 9, 2023. Warning Against Solicitation, Fraudulent Emails, etc. that Use the Name of Eisai or Related Parties. February 17, 2023. EISAI SUPPORTS RELIEF EFFORTS FOR EARTHQUAKE IN TURKEY AND ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205686+00:00",
              "published_date": null,
              "source_hash": "7089ca99bbf4c5b87473b557fe516c10"
            },
            {
              "url": "",
              "title": "Eisai Receives Positive Opinion from the CHMP in the European Union for ...",
              "snippet": "For Print; November 15, 2024; TOKYO and CAMBRIDGE, Mass., November 15, 2024 - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \"Biogen\") announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205709+00:00",
              "published_date": null,
              "source_hash": "51b4f52d345c4ea5b7e1b6c70887a934"
            },
            {
              "url": "",
              "title": "Eisai to share updates on Alzheimer's disease pipeline at CTAD 2024 ...",
              "snippet": "Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. 4.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205733+00:00",
              "published_date": null,
              "source_hash": "77e4eb87a0ef2e75ac11895b2976e177"
            },
            {
              "url": "",
              "title": "Eisai Named to List of The Time 100 Most Influential Companies",
              "snippet": "Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product and Eisai having final decision-making authority. Please see full Prescribing Information, including Boxed WARNING in the United States. MEDIA CONTACTS: Eisai Co., Ltd.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205755+00:00",
              "published_date": null,
              "source_hash": "282d6391852a3e9ccff8cb08f5732a0e"
            },
            {
              "url": "",
              "title": "LEQEMBI Alzheimer's treatment approved in South Korea | Eisai US",
              "snippet": "Eisai and Biogen received approval from the Ministry of Food and Drug Safety to treat dementia, starting in the private market with a Patient Assistance Program. ... Mass., Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito ... Eisai serves as the lead of LEQEMBI development and regulatory submissions globally ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205776+00:00",
              "published_date": null,
              "source_hash": "43af26dddd0cbf5deb8ce259ff89b3b2"
            },
            {
              "url": "",
              "title": "Eisai Co Ltd | Reuters",
              "snippet": "The latest international Eisai Co Ltd news and views from Reuters - one of the world's largest news agencies. ... Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:08.205798+00:00",
              "published_date": null,
              "source_hash": "86293f329e426617ce9c3ee87b504218"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (ESAIY)",
              "snippet": "Eisai Co., Ltd. (Headquarters: Tokyo ... to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI\u00ae) subcutaneous autoinjector for weekly maintenance dosing ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:10.542748+00:00",
              "published_date": "2024-12-31T00:00:00+00:00",
              "source_hash": "5b6799fa34881a98cd8d261b7fd5c476"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (4523.T)",
              "snippet": "Eisai Co., Ltd. (Headquarters: Tokyo ... to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI\u00ae) subcutaneous autoinjector for weekly maintenance dosing ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:10.542852+00:00",
              "published_date": "2024-12-08T18:55:00+00:00",
              "source_hash": "8dc5d7f240c6e63e7b24d6fc0f0a2b71"
            },
            {
              "url": "",
              "title": "Eisai stock slumps after Alzheimer's drug fails to get approval in Europe",
              "snippet": "Eisai shares fell sharply after its Alzheimer's drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:10.542881+00:00",
              "published_date": "2024-07-29T02:51:00+00:00",
              "source_hash": "868e3a917591c261381c73472fdb57e7"
            },
            {
              "url": "",
              "title": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
              "snippet": "Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd ... approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:10.542906+00:00",
              "published_date": "2024-11-14T16:24:00+00:00",
              "source_hash": "e5383969b34876a9face828a6f63fb8e"
            },
            {
              "url": "",
              "title": "\"LEQEMBI\u00ae\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea",
              "snippet": "Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd ... regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. regulatory challenges drug approvals",
              "retrieved_at": "2025-01-06T19:40:10.542929+00:00",
              "published_date": "2024-11-28T00:00:00+00:00",
              "source_hash": "d899a04a6b5e0cb53918fbdc32087e96"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd.\uff5cA human health care company",
              "snippet": "Welcome to the Eisai Official Corporate Website Eisai Co., Ltd. Page. Menu. Eisai's hhc Concept; Innovation. Back. Innovation. Research and Development (R&D) hhceco (the hhc Concept ... Introducing Eisai DE&I: Now and the Future. Learn more \"Diversity, Equity and Inclusion\" Page Renewal.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292113+00:00",
              "published_date": null,
              "source_hash": "381e4d40709dfa4a9f12e18127f2a7aa"
            },
            {
              "url": "",
              "title": "Corporate Information | About Eisai | Eisai Co., Ltd.",
              "snippet": "Eisai Co., Ltd. Date Established: December 6, 1941 History; Head Office: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan Google Maps; Vicinity map for Headquarters; Japan Business Sites; Telephone: 81-3-3817-3700: Representatives: Haruo Naito, Representative Corporate Officer and CEO",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292252+00:00",
              "published_date": null,
              "source_hash": "ed5b848b196b520243241f5634488cb5"
            },
            {
              "url": "",
              "title": "About Eisai - Eisai Co., Ltd.",
              "snippet": "Welcome to the Eisai Official Corporate Website About Eisai Page.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292312+00:00",
              "published_date": null,
              "source_hash": "bdd2632699fdf96e74f8a900898f48bb"
            },
            {
              "url": "",
              "title": "Eisai Co, Ltd | Access to Medicine",
              "snippet": "Eisai Co, Ltd. Stock exchange: Tokyo Stock Exchange \u30fb Ticker: ESALY \u30fb HQ: Tokyo, Japan \u30fb Access to Medicine Index. 14. Rank. 2.62. Score. The full report card of Eisai Co, Ltd in PDF format. ... However, it does disclose anonymised disaggregated R&D investment data to Impact Global Health (formerly Policy Cures Research). ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292333+00:00",
              "published_date": null,
              "source_hash": "32c311703c17e77e1036870530ac453d"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (ESAIY) Stock Price & Overview - Stock Analysis",
              "snippet": "About Eisai. Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144343+00:00",
              "published_date": null,
              "source_hash": "6e301bc6c2633736d14859e57ed8cb40"
            },
            {
              "url": "",
              "title": "Eisai Co Ltd | Reuters",
              "snippet": "The latest international Eisai Co Ltd news and views from Reuters - one of the world's largest news agencies",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292355+00:00",
              "published_date": null,
              "source_hash": "1103c2413966db9569fab1b460aba192"
            },
            {
              "url": "",
              "title": "Eisai Co Ltd - Company Profile and News - Bloomberg Markets",
              "snippet": "Eisai Co., Ltd. produces prescription drugs and medical equipment, and sells mainly to sales agents and subsidiaries. Through its subsidiary, the Company produces and sells diagnostic drugs. Eisai ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292364+00:00",
              "published_date": null,
              "source_hash": "3e00acc6421200e42245afb23e421613"
            },
            {
              "url": "",
              "title": "EISAI CO., LTD. Company Profile - Dun & Bradstreet",
              "snippet": "EISAI CO., LTD. Website. Get a D&B Hoovers Free Trial. Overview Company Description: Eisai is a leading global pharmaceutical company. It develops, manufactures, and distributes prescription pharmaceuticals throughout the world. Eisai promotes creating solutions (new drugs) based on scientific evidence in the areas of its expertise: neurology ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292374+00:00",
              "published_date": null,
              "source_hash": "4152ee8e5a5a6372f79632a08f25aa3c"
            },
            {
              "url": "",
              "title": "Eisai Newsroom - Press Releases",
              "snippet": "Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \"Eisai\") announced today that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "retrieved_at": "2025-01-06T19:40:12.292384+00:00",
              "published_date": null,
              "source_hash": "45f90e53add9d66c37371022219deb7b"
            },
            {
              "url": "",
              "title": "ESALF Stock Price | Eisai Co. Ltd. Stock Quote (U.S.: OTC) - MarketWatch",
              "snippet": "Q1 2025 Eisai Co Ltd Earnings Presentation Transcript Oct. 9, 2024 at 2:16 p.m. ET on GuruFocus.com The 7 Best Growth Stocks to Buy for February 2023",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144274+00:00",
              "published_date": null,
              "source_hash": "74a4e9e94c68c7ad14b6157899a68647"
            },
            {
              "url": "",
              "title": "ESAIY Stock Price | Eisai Co. Ltd. ADR Stock Quote (U.S.: OTC ...",
              "snippet": "View the latest market news and prices, and trading information. ... U.S. Market Movers. Trending Tickers by Volume; ... Eisai Co. Ltd. ADR. Eisai Co., Ltd. engages in the development, manufacture ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144328+00:00",
              "published_date": null,
              "source_hash": "8e3f7a6acee9f95c8d4f6fe6ceaf9ca1"
            },
            {
              "url": "",
              "title": "4523.T - | Stock Price & Latest News | Reuters",
              "snippet": "Get Eisai Co Ltd (4523.T) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Exclusive news, data and analytics for financial market ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144355+00:00",
              "published_date": null,
              "source_hash": "c2fa56cc895f1c0a7bda1bba5d11cd6b"
            },
            {
              "url": "",
              "title": "ESAIY: Eisai Co Ltd Stock Price Quote - OTC US - Bloomberg",
              "snippet": "Stock analysis for Eisai Co Ltd (ESAIY:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144364+00:00",
              "published_date": null,
              "source_hash": "8db8ea9c6206d921a0418f22223fd30b"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (4523.T) - Yahoo Finance",
              "snippet": "Find the latest Eisai Co., Ltd. (4523.T) stock quote, history, news and other vital information to help you with your stock trading and investing.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144374+00:00",
              "published_date": null,
              "source_hash": "5d01a50195fad12b64584275558235cb"
            },
            {
              "url": "",
              "title": "Eisai Co Ltd, 4523:TYO summary - FT.com - Financial Times",
              "snippet": "Latest Eisai Co Ltd (4523:TYO) share price with interactive charts, historical prices, comparative analysis, ... Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. ... View funds that move the market, screen for funds and read relevant ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144382+00:00",
              "published_date": null,
              "source_hash": "0e56ae188d9a25ce9b942d0d07b77f01"
            },
            {
              "url": "",
              "title": "ESAIY | Eisai Co. Ltd. ADR Profile | MarketWatch",
              "snippet": "Eisai Co. Ltd. ADR company facts, information and financial ratios from MarketWatch. ... U.S. Market Movers. Trending Tickers by Volume; Premarket Movers; ... Price to Book Ratio: 2.04: Price to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144392+00:00",
              "published_date": null,
              "source_hash": "012636085cb903456b4eba3ff62b9e9f"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (ESAIY) Statistics & Valuation Metrics - Stock Analysis",
              "snippet": "Detailed statistics for Eisai Co., Ltd. (ESAIY) stock, including valuation metrics, financial numbers, share information and more. ... Eisai has a market cap or net worth of 7.64 billion. The enterprise value is 7.25 billion. Market Cap: ... so Eisai's price volatility has been lower than the market average. Beta (5Y) -0.08: 52-Week Price ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144401+00:00",
              "published_date": null,
              "source_hash": "3183e65da572110a94b0c5795626e282"
            },
            {
              "url": "",
              "title": "Eisai Co Ltd, 4523:TYO profile - FT.com - Financial Times",
              "snippet": "Year on year Eisai Co Ltd 's net income fell -23.50% from 55.43bn to 42.41bn despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 46.77% to 49.08%.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:18.144410+00:00",
              "published_date": null,
              "source_hash": "1bb49aa849b84f2b0ab07b8359db8989"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (ESAIY)",
              "snippet": "Eisai Co., Ltd. (Headquarters: Tokyo ... the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:20.542304+00:00",
              "published_date": "2024-12-31T00:00:00+00:00",
              "source_hash": "3fcbbce4e61ca0e9ae610dd1b5f6d020"
            },
            {
              "url": "",
              "title": "Eisai Co. Ltd. ADR",
              "snippet": "The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:20.542340+00:00",
              "published_date": "2023-07-07T16:55:00+00:00",
              "source_hash": "8fe31dcb182a00d5d08dc3b6dfa5aefc"
            },
            {
              "url": "",
              "title": "Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease",
              "snippet": "Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters ... report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:20.542353+00:00",
              "published_date": "2024-11-14T16:24:00+00:00",
              "source_hash": "c6a03eaeb52ba46f24ef53a4b4bba225"
            },
            {
              "url": "",
              "title": "Eisai lowers Leqembi revenue forecast after rocky entry to market",
              "snippet": "Eisai has lowered the sales forecast for its Alzheimer's drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:20.542363+00:00",
              "published_date": "2024-11-08T22:13:00+00:00",
              "source_hash": "b4d2c0db83dedd913fc2bdebbda62980"
            },
            {
              "url": "",
              "title": "Eisai Co., Ltd. (ESALF)",
              "snippet": "Eisai Co., Ltd. (Headquarters: Tokyo ... the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Eisai Co. Ltd. Eisai Co. Ltd. pricing pressures U.S. market",
              "retrieved_at": "2025-01-06T19:40:20.542373+00:00",
              "published_date": "2024-11-29T15:00:00+00:00",
              "source_hash": "3123d3111f553d054aec0edc6ff49304"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Eisai Co. Ltd. regulatory challenges drug approvals",
              "rationale": "Investigate potential delays or issues in drug approvals that could impact revenue and market position",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "Eisai Co. Ltd. Belviq withdrawal impact on reputation",
              "rationale": "Assess the long-term effects of the Belviq withdrawal on Eisai's reputation and public trust",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "Eisai Co. Ltd. pricing pressures U.S. market",
              "rationale": "Examine the impact of drug pricing scrutiny on Eisai's profitability in the U.S. market",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:40:38.544010",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}